Indication: Medulloblastoma

Phase II Trial of Eflornithine/DFMO as Maintenance Therapy for Molecular High Risk/Very High Risk and Relapsed/Refractory Medulloblastoma

Sub-indication: Medulloblastoma

Drug Study

Principal Investigator: Michael Huang, M.D.
Norton Children's Cancer Institute, affiliated with the UofL School of Medicine

Sponsor: Beat Childhood Cancer

Search our entire site.